UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of March 2026
Commission File Number: 001-36622
PROQR THERAPEUTICS N.V.
Zernikedreef 9
2333 CK Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including Zip Code, and Telephone
Number,
Including Area Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F
x Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On March 25, 2026,
ProQR Therapeutics N.V. (“ProQR”) issued a press release titled “ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026.” A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
ProQR hereby incorporates by reference the information
contained herein into ProQR’s registration statements on Form F-3 (File No. 333-282419, File No. 333-270943, File
No. 333-263166 and File No. 333-285767).
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
PROQR THERAPEUTICS N.V. |
| |
|
| Date: March 25, 2026 |
By: |
/s/ Dennis Hom |
| |
|
Dennis Hom |
| |
|
Chief Financial Officer |
INDEX TO EXHIBITS
| Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release of ProQR Therapeutics N.V. dated March 25, 2026. |
Exhibit 99.1
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline
on April 8, 2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2026 –
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its
proprietary Axiomer™ RNA editing technology platform, today announced that it will host a virtual Investor and Analyst Event highlighting
its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond
AX-0810”
Ahead of the anticipated target engagement data for AX-0810 in the
first half of 2026, the Company will showcase ProQR’s broader RNA editing pipeline at this event, announce new programs that will
have clinical data readouts in the runway, and unveil the primary indication for AX-0810.
Event Details and Registration
| · | Title:
Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810 |
| · | Date
& Time: April 8, 2026 beginning at 10:00 am ET until approximately 11:30 am ET |
| · | Virtual
format: Webcast presentations and Q&A with covering analysts and Management |
| · | Registration:
https://lifescievents.com/event/g09gufqylu/ |
About Axiomer™
ProQR is pioneering a next-generation RNA base editing technology
called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™
“Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using
molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are
designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine
is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating
protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation
of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a
cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein
expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique
proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
Forward Looking Statements
This press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,”
"anticipate," "believe," "could," "estimate," "expect," "goal," "intend,"
"look forward to", "may," "plan," "potential," "predict," "project," "should,"
"will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements
regarding our business, technology, strategy, preclinical and clinical model data; our initial pipeline targets and the upcoming strategic
priorities and milestones related thereto; our new pipeline targets, the continued advancement of our lead development pipeline programs,
including approved, ongoing and planned clinical trials; expectations regarding the ongoing Phase 1 clinical study of AX-0810 in NTCP
for cholestatic diseases; expectations regarding the safety and therapeutic benefits of AX-0810, including the planned dosing levels
and their efficacy; the anticipated timing of initial Phase 1 clinical data for our lead program, AX-0810, in H1, 2026, and clinical
updates across multiple programs in 2026; the continued development and advancement of our Axiomer™ platform; the therapeutic
potential of our Axiomer RNA editing oligonucleotides and product candidates; the timing, progress and results of our preclinical studies
and other development activities, including the release of data related thereto; our patent estate, including our anticipated strength
and our continued investment in it; and the potential of our technologies and product candidates. Forward-looking statements are based
on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual
results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without
limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain
sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and
results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations
and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions, U.S. government
shutdown and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines
provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance
our clinical trials and maintain their own operations; our reliance on contract manufacturers to supply materials for research and development
and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results
of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances
that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize
the intended benefits of collaborations with partners, including the collaboration with Lilly; the possible impairment of, inability
to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated
in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes
with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments,
geopolitical events and conflicts, high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies
and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the
future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
